Joshua Brody, MD
-
- Positions
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSOCIATE PROFESSOR | Oncological Sciences
-
- Specialties
- Cancer (Oncology)
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
-
Ruttenberg Treatment Center
1470 Madison Avenue
3rd Floor
New York, NY 10029
Phone: 212-241-6756212-241-6756
Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery. Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.
Dr. Brody’s research receives funding from numerous grantors, including the National Institutes of Health, the Cancer Research Institute, the Damon Runyon Cancer Research Foundation, and the Lymphoma Research Foundation. He is a member of many professional organizations, including the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology.
Dr. Brody is committed to partnering with his patients to choose the most appropriate treatment approach that offers the best outcomes with excellent quality of life.
Clinical Focus
- Adult Non-Hodgkin's Lymphoma
- Hodgkin's Disease
- Hodgkin's Lymphoma
- Leukemia
- Lymphoma
- Mantle Cell Lymphoma
- Primary Central Nervous System Lymphoma
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
Education
BA, Harvard University
MD, SUNY StonyBrook Medical Center
MD, State University of New York Stony Brook School of Medicine
Residency, Internal Medicine
Yale University Health Services
Fellowship, Medical Oncology
Stanford University School of Medicine
Language
English
2011
Society for Immunotherapy of Cancer Presidential Award (SITC 26th Annual Meeting)
Society for the Immunotherapy of Cancer
2011
SCL Award for top abstract submitted to 2011 International Conference on Malignant Lymphoma
Swiss Cancer League
2011
ASCO Merit Award for top 100 abstracts submitted to 2011 Annual Meeting
American Society of Clinical Oncology
2009
Howard Temin Pathway to Independence Award in Cancer Research (K99/R00) – [1 K99 CA140728-01] ”Immunotransplant to Treat Lymphoma” – 09/09 – 08/14
NCI
2009
‘Outstanding Recent Graduate’
SUNY Stony Brook School of Medicine
2008
ASCO Bradley Stuart Beller Foundation Fellowship Merit Award for best abstract submitted to 2008 Annual Meeting
American Society of Clinical Oncology
2008
William Guy Forbeck Scholar Award – invited to present at 2008 Forum
William Guy Forbeck Research Foundation
2008
MCLC featured researcher
Mantle Cell Lymphoma Consortium
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Brody during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Acerta Pharma
- Bristol-Myers Squibb
- Genentech, Inc.
- Janssen Pharmaceuticals, Inc.
- Kite-Gilead
- Merck & Co., Inc.
- Seattle Genetics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.